Literature DB >> 1323350

Transforming growth factor beta 1 (TGF beta 1) reduces cellular levels of p34cdc2, and this effect is abrogated by adenovirus independently of the E1A-associated pRB binding activity.

S E Abraham1, M C Carter, E Moran.   

Abstract

We have used E1A probes to study the roles of the p34cdc2 kinase and the retinoblastoma tumor susceptibility gene product (pRB) in transforming growth factor beta 1 (TGF beta 1)-mediated growth suppression in mink lung epithelial (Mv1Lu) cells. In agreement with previous reports, we see a decline in p34cdc2 kinase activity and a loss of pRB phosphorylation after TGF beta 1 treatment. We report here that TGF beta 1 induces not only a change in p34cdc2 kinase activity but a strong repression of p34cdc2 synthesis. Loss of p34cdc2 kinase activity is not seen until the steady-state level of p34cdc2 declines, suggesting that the intra-cellular signals induced by TGF beta 1 affect p34cdc2 at the level of expression, rather than by altering the posttranslational modifications of p34cdc2 that regulate its kinase activity. Infection with adenovirus expressing either wild-type E1A or a mutant E1A (pm928) defective for pRB binding alleviated TGF beta 1-mediated suppression of DNA synthesis, indicating that E1A does not need to bind pRB physically to keep cell growth-suppressing functions from being activated by TGF beta 1. The E1A.928 mutant virus is able to maintain p34cdc2 expression and kinase activity, as well as pRB phosphorylation in the presence of TGF beta 1, which may account for its ability to maintain cell cycle activity without directly sequestering pRB. Overall our results suggest that TGF beta 1 acts by signaling changes at the level of control of G1 gene expression, not at the level of posttranslational modification of p34cdc2 or its substrates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323350      PMCID: PMC275620          DOI: 10.1091/mbc.3.6.655

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  54 in total

1.  cdc2 gene expression at the G1 to S transition in human T lymphocytes.

Authors:  Y Furukawa; H Piwnica-Worms; T J Ernst; Y Kanakura; J D Griffin
Journal:  Science       Date:  1990-11-09       Impact factor: 47.728

2.  A cdc2-like protein is involved in the initiation of DNA replication in Xenopus egg extracts.

Authors:  J J Blow; P Nurse
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

3.  Identification of separate domains in the adenovirus E1A gene for immortalization activity and the activation of virus early genes.

Authors:  E Moran; B Zerler; T M Harrison; M B Mathews
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

4.  Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate.

Authors:  G Draetta; H Piwnica-Worms; D Morrison; B Druker; T Roberts; D Beach
Journal:  Nature       Date:  1988 Dec 22-29       Impact factor: 49.962

5.  Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement.

Authors:  G Draetta; D Beach
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

6.  Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product.

Authors:  P Whyte; K J Buchkovich; J M Horowitz; S H Friend; M Raybuck; R A Weinberg; E Harlow
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

7.  A region of SV40 large T antigen can substitute for a transforming domain of the adenovirus E1A products.

Authors:  E Moran
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

8.  Regulated expression and phosphorylation of a possible mammalian cell-cycle control protein.

Authors:  M G Lee; C J Norbury; N K Spurr; P Nurse
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

9.  Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells.

Authors:  Y Furukawa; J A DeCaprio; A Freedman; Y Kanakura; M Nakamura; T J Ernst; D M Livingston; J D Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

10.  p13suc1 acts in the fission yeast cell division cycle as a component of the p34cdc2 protein kinase.

Authors:  L Brizuela; G Draetta; D Beach
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  7 in total

Review 1.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

2.  p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes.

Authors:  P B Dallas; I W Cheney; D W Liao; V Bowrin; W Byam; S Pacchione; R Kobayashi; P Yaciuk; E Moran
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

3.  TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein.

Authors:  X Shen; P P Hu; N T Liberati; M B Datto; J P Frederick; X F Wang
Journal:  Mol Biol Cell       Date:  1998-12       Impact factor: 4.138

4.  Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein.

Authors:  J O Funk; S Waga; J B Harry; E Espling; B Stillman; D A Galloway
Journal:  Genes Dev       Date:  1997-08-15       Impact factor: 11.361

5.  The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B.

Authors:  M B Datto; P P Hu; T F Kowalik; J Yingling; X F Wang
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

Review 6.  Transforming growth factor beta and the cell surface in tumor progression.

Authors:  M J Newman
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

7.  Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation.

Authors:  G W Demers; E Espling; J B Harry; B G Etscheid; D A Galloway
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.